Harris Sliwoski Hosts Live Rescheduling Analysis After DEA Hearing

Live Webcast Set for July 22

Harris Sliwoski will stream a live analysis of the DEA rescheduling hearing on July 22, 2026, featuring cannabis regulatory attorney Jason Adelstone. The webcast follows the conclusion of the DEA's administrative law judge hearing on the proposed rule to reclassify cannabis as a Schedule III controlled substance. Adelstone has tracked the rescheduling process since HHS submitted its scientific recommendation to the DEA in August 2023.

Real-time questions are welcome. The Cannabis Brief LIVE format allows industry stakeholders to pose questions as the session unfolds. Registration is open through the Harris Sliwoski website.

DEA Hearing Timeline and Procedural Status

The DEA administrative hearing concluded in July 2026 after reviewing public comments and expert testimony on the HHS recommendation to reschedule cannabis. Under the Administrative Procedure Act, the DEA must now compile the hearing record, allow post-hearing briefs, and issue a final rule through the Federal Register. The agency hasn't announced a deadline for the final determination.

President Biden directed HHS to review cannabis scheduling in October 2022. That's when the rescheduling process began. HHS completed its review in August 2023 and recommended Schedule III placement based on medical utility findings. The DEA published a notice of proposed rulemaking in May 2024 and scheduled the administrative hearing for June-July 2026.

Schedule III Tax Implications Under IRC §280E

Reclassification to Schedule III would eliminate IRC §280E restrictions for state-licensed cannabis operators, allowing standard business expense deductions. Section 280E prohibits businesses trafficking in Schedule I or Schedule II substances from deducting ordinary business expenses on federal tax returns. Cannabis operators currently deduct only cost of goods sold.

The tax impact varies by business model:

• Vertically integrated MSOs: 15-25% effective tax rate reduction
• Cultivation-only operators: minimal impact (COGS already deductible)
• Retail-only operators: 30-40% effective tax rate reduction
• Ancillary service providers: no change (280E doesn't apply)

The Congressional Research Service estimated Schedule III reclassification would reduce federal tax revenue by $3.1 billion annually once fully implemented.

State-Level Regulatory Implications

Schedule III placement doesn't alter state cannabis laws but may trigger compliance reviews in states with CSA-linked statutes. Seventeen states reference the federal Controlled Substances Act in their controlled substance schedules. Rescheduling could require those states to amend statutes or regulations to maintain cannabis prohibitions or medical-only frameworks.

State legislatures in jurisdictions with CSA cross-references will face a choice: amend their controlled substance acts to decouple from federal scheduling, or allow automatic reclassification under state law.

States with independent scheduling authority—including California, Colorado, and Michigan—will see no automatic legal changes. For comprehensive background on the rescheduling timeline and state-by-state implications, see the CannIntel topic hub on DEA cannabis rescheduling.

What to Watch After the Hearing

The next procedural milestone is the DEA's publication of the administrative law judge recommendation and the agency's final rule adopting or rejecting that recommendation. The DEA isn't bound by the ALJ recommendation. It typically follows the recommendation absent compelling policy grounds for deviation. Legal challenges are expected regardless of the outcome, with potential plaintiffs including prohibitionist groups, medical cannabis advocates, and hemp industry stakeholders.

If the DEA finalizes Schedule III reclassification, the effective date will be specified in the Federal Register notice. Tax practitioners expect a 60-90 day implementation window for IRC §280E relief.